Menu Search
Equities

ProQR Therapeutics NV

PRQR:NAQ

ProQR Therapeutics NV

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.77
  • Today's Change0.20 / 5.60%
  • Shares traded997.02k
  • 1 Year change+179.26%
  • Beta0.2307
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year ProQR Therapeutics NV grew revenues 118.51% from 4.36m to 9.53m while net income improved from a loss of 64.42m to a smaller loss of 28.12m.
Gross margin--
Net profit margin-113.62%
Operating margin-128.18%
Return on assets-15.98%
Return on equity-50.90%
Return on investment-20.63%
More ▼

Cash flow in EURView more

In 2023, ProQR Therapeutics NV increased its cash reserves by 25.48%, or 24.15m. The company earned 21.55m from its operations for a Cash Flow Margin of 226.23%. In addition the company generated 4.28m cash from investing, though they paid out 2.28m more in financing than they received.
Cash flow per share-0.2435
Price/Cash flow per share--
Book value per share0.418
Tangible book value per share0.418
More ▼

Balance sheet in EURView more

ProQR Therapeutics NV appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.30% of the market capitalization can be attributed to its 118.93m and debt could be paid in full if management chose.
Current ratio2.73
Quick ratio--
Total debt/total equity0.5841
Total debt/total capital0.3687
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.